Correlation between increasing EFS and use of health care
| Use of health care per mo of OS . | Coefficient of correlation . | P . | |
|---|---|---|---|
| r . | 95% CI . | ||
| All patients | |||
| Overall use of health care | −0.45 | −0.53 to −0.37 | <.001 |
| Clinic visits | −0.38 | −0.46 to −0.29 | <.001 |
| ER visits | −0.15 | −0.24 to −0.05 | .004 |
| Hospital admissions | −0.34 | −0.43 to −0.25 | <.001 |
| Consultations from other services | −0.39 | −0.47 to −0.30 | <.001 |
| Blood product transfusions | −0.18 | −0.28 to −0.09 | <.001 |
| Laboratory studies | −0.51 | −0.58 to −0.44 | <.001 |
| Imaging studies | −0.38 | −0.46 to −0.29 | <.001 |
| Invasive procedures | −0.49 | −0.56 to −0.41 | <.001 |
| Patients with CR (n = 286) | |||
| Overall use of health care | −0.52 | −0.60 to −0.43 | <.001 |
| Combined clinic visits, ER visits, hospitalizations, and consultations | −0.51 | −0.59 to −0.42 | <.001 |
| Combined invasive procedures, imaging studies, and laboratory studies | −0.60 | −0.67 to −0.52 | <.001 |
| Blood product transfusions | −0.20 | −0.31 to −0.09 | <.001 |
| Hospitalizations | −0.36 | −0.46 to −0.25 | <.001 |
| ER visits | −0.17 | −0.28 to −0.06 | .003 |
| Overall use of health care in ELN risk groups | |||
| Favorable (n = 29) | −0.36 | −0.64 to 0.01 | .06 |
| Intermediate (n = 230) | −0.40 | −0.50 to −0.29 | <.001 |
| Adverse (n = 141) | −0.55 | −0.66 to −0.42 | <.001 |
| Overall use health care according to age, y | |||
| <65 (n = 193) | −0.43 | −0.54 to −0.31 | <.001 |
| ≥65 (n = 207) | −0.41 | −0.52 to −0.29 | <.001 |
| Overall use of health care according to therapy | |||
| Intensive chemotherapy with or without other agents (n = 188)* | −0.47 | −0.57 to −0.34 | <.001 |
| HMA with or without other agents or chemotherapy (n = 109)† | −0.47 | −0.61 to −0.20 | <.001 |
| NIC with or without other agents (n = 93)* | −0.43 | −0.58 to −0.24 | <.001 |
| Use of health care per mo of OS . | Coefficient of correlation . | P . | |
|---|---|---|---|
| r . | 95% CI . | ||
| All patients | |||
| Overall use of health care | −0.45 | −0.53 to −0.37 | <.001 |
| Clinic visits | −0.38 | −0.46 to −0.29 | <.001 |
| ER visits | −0.15 | −0.24 to −0.05 | .004 |
| Hospital admissions | −0.34 | −0.43 to −0.25 | <.001 |
| Consultations from other services | −0.39 | −0.47 to −0.30 | <.001 |
| Blood product transfusions | −0.18 | −0.28 to −0.09 | <.001 |
| Laboratory studies | −0.51 | −0.58 to −0.44 | <.001 |
| Imaging studies | −0.38 | −0.46 to −0.29 | <.001 |
| Invasive procedures | −0.49 | −0.56 to −0.41 | <.001 |
| Patients with CR (n = 286) | |||
| Overall use of health care | −0.52 | −0.60 to −0.43 | <.001 |
| Combined clinic visits, ER visits, hospitalizations, and consultations | −0.51 | −0.59 to −0.42 | <.001 |
| Combined invasive procedures, imaging studies, and laboratory studies | −0.60 | −0.67 to −0.52 | <.001 |
| Blood product transfusions | −0.20 | −0.31 to −0.09 | <.001 |
| Hospitalizations | −0.36 | −0.46 to −0.25 | <.001 |
| ER visits | −0.17 | −0.28 to −0.06 | .003 |
| Overall use of health care in ELN risk groups | |||
| Favorable (n = 29) | −0.36 | −0.64 to 0.01 | .06 |
| Intermediate (n = 230) | −0.40 | −0.50 to −0.29 | <.001 |
| Adverse (n = 141) | −0.55 | −0.66 to −0.42 | <.001 |
| Overall use health care according to age, y | |||
| <65 (n = 193) | −0.43 | −0.54 to −0.31 | <.001 |
| ≥65 (n = 207) | −0.41 | −0.52 to −0.29 | <.001 |
| Overall use of health care according to therapy | |||
| Intensive chemotherapy with or without other agents (n = 188)* | −0.47 | −0.57 to −0.34 | <.001 |
| HMA with or without other agents or chemotherapy (n = 109)† | −0.47 | −0.61 to −0.20 | <.001 |
| NIC with or without other agents (n = 93)* | −0.43 | −0.58 to −0.24 | <.001 |